Illinois Enacts Trio of LGBTQ+ Health and Privacy Laws, Expands Hormone Access and Protects Gender Identity Rights
Illinois Gov. JB Pritzker has signed three new laws aimed at strengthening privacy protections, expanding access to hormone therapy and cementing gender identity rights for LGBTQ+ residents and visitors.
Standing with legislators and advocates ahead of the Chicago Pride Parade, Pritzker framed the package as part of a broader effort to ensure people can “live authentically and freely” in Illinois without fear that their medical information or identity documents will be turned against them.
“Who you are, how you access health care, and the decisions you make about your own body should be met with respect — not barriers or fear,” said Lieutenant Governor Juliana Stratton. “These laws send a clear message to our LGBTQ+ community that you belong, your rights matter, and Illinois will continue to protect your dignity, privacy, and freedom. I’m proud that our state continues to lead by standing up for the rights and freedoms of every resident.”
The measures focus on tightening controls around prescription data, guaranteeing access to longer-term hormone therapy, and codifying the ability to choose one’s gender marker on state-issued identification.
The ILPMP, used by more than 30 states to track certain medications, has come under scrutiny as some states restrict gender-affirming and reproductive care, raising concerns that prescription data could be used to investigate or punish patients. HB 4834 removes testosterone from Illinois’ Prescription Monitoring Program (ILPMP) and bars the addition of estrogen, mifepristone and misoprostol to the database.
HB 5095 formally writes into state law the Secretary of State’s existing self-attestation process for correcting gender markers on driver’s licenses and state IDs, allowing Illinois residents to choose male, female or X to reflect their gender identity. The legislation also requires that gender marker information reported by residents remain confidential.
The third measure, HB 5492, requires insurance companies to cover up to a six‑month supply of prescribed hormone therapy when a healthcare provider or pharmacist deems a larger supply clinically appropriate. Supporters say bulk dispensing will help patients maintain continuity of care and reduce logistical and financial hurdles.
